

## Appendix 6: Full national audit results – paediatric services

### Crohn's disease details

CD: disease details	Frequency (% , n)		
	Adalimumab (Humira) (n=19)	Infliximab (Inflectra/Remsima) (n=63)	Infliximab (Remicade) (n=129)
<b>Diagnosis</b>			
<b>Maximal disease distribution at the time of decision to initiate biological therapy, as defined by the Montreal classification</b>	<b>(n=18)</b>	<b>(n=61)</b>	<b>(n=127)</b>
Terminal ileum (L1)	50% (9)	15% (9)	8% (10)
Colonic (L2)	17% (3)	20% (12)	24% (30)
Ileocolonic (L3)	28% (5)	57% (35)	62% (79)
None of these	6% (1)	8% (5)	6% (8)
<b>Any part of the gut proximal to the terminal ileum (L4)?</b>	<b>(n=17)</b>	<b>(n=51)</b>	<b>(n=109)</b>
Yes	41% (7)	69% (35)	54% (59)
<b>Perianal involvement?</b>	<b>(n=17)</b>	<b>(n=45)</b>	<b>(n=106)</b>
Yes	35% (6)	44% (20)	48% (51)

CD = Crohn's disease.

## Crohn's disease initial treatment

CD: initial treatment	Frequency (% , n)		
	Adalimumab (Humira) (n=19)	Infliximab (Inflectra/Remsima) (n=63)	Infliximab (Remicade) (n=129)
<b>Treatment details</b>			
<b>Is the patient biologics naïve?</b>	<b>(n=17)</b>	<b>(n=43)</b>	<b>(n=103)</b>
Yes	100% (17)	98% (42)	100% (103)
No	0% (0)	2% (1)	0% (0)
<b>If not naïve select reason</b>			
Loss of response	0% (0)	100% (1)	0% (0)
<b>Time between date of diagnosis and date of initial treatment</b>		<b>(n=60)</b>	<b>(n=128)</b>
<1 year	84% (16)	47% (28)	55% (70)
1–2 years	11% (2)	27% (16)	26% (33)
3–5 years	5% (1)	22% (13)	15% (19)
6–10 years	0% (0)	5% (3)	4% (5)
>10 years	0% (0)	0% (0)	0.8% (1)
<b>What was the clinical indication for this treatment?</b>		<b>(n=61)</b>	<b>(n=128)</b>
Severe perianal CD	5% (1)	16% (10)	11% (14)
Active luminal CD	95% (18)	79% (48)	77% (99)
Fistulating CD	0% (0)	2% (1)	9% (11)
Other clinical indication	0% (0)	3% (2)	0.8% (1)
Not known	0% (0)	0% (0)	2% (3)
<b>Were any acute reactions or adverse events recorded for this treatment?</b>	<b>(n=17)</b>	<b>(n=43)</b>	<b>(n=104)</b>
Yes	6% (1)	0% (0)	3% (3)

CD = Crohn's disease.

CD: initial treatment	Frequency (% , n)		
	Adalimumab (Humira) (n=19)	Infliximab (Inflectra/Remsima) (n=63)	Infliximab (Remicade) (n=129)
<b>Treatment details</b>			
<b>Is the patient receiving any concomitant therapies for the management of IBD at the time of this treatment?</b>			
Yes	90% (17)	95% (60)	95% (122)
<b>If yes, indicate which concomitant therapies (more than one may have been selected)</b>			
Allopurinol	0% (0)	3% (2)	2% (3)
Azathioprine/mercaptopurine	84% (16)	81% (51)	85% (110)
5-aminosalicylic acid	16% (3)	14% (9)	20% (26)
Antibiotics	0% (0)	8% (5)	9% (11)
Ciclosporin	0% (0)	0% (0)	0% (0)
Dietary therapy	0% (0)	19% (12)	17% (22)
Methotrexate	5% (1)	5% (3)	5% (7)
Mycophenolate	0% (0)	0% (0)	0% (0)
Steroids	5% (1)	18% (11)	18% (23)
Tacrolimus	0% (0)	0% (0)	0% (0)
Topical	0% (0)	2% (1)	2% (2)
Other	0% (0)	8% (5)	2% (2)

IBD = inflammatory bowel disease; CD = Crohn's disease.

National clinical audit of biological therapies. Full national audit results – paediatric services. September 2016. UK IBD audit

CD: initial treatment	Frequency (% , n)		
	Adalimumab (Humira) (n=19)	Infliximab (Inflectra/Remsima) (n=63)	Infliximab (Remicade) (n=129)
<b>Treatment details</b>			
<b>Has the patient failed to respond or are they intolerant to immunosuppressive drugs / corticosteroids?</b>			
Yes	95% (18)	62% (39)	76% (98)
<b>If yes, indicate which previous therapies (more than one may have been selected)</b>			
Allopurinol	0% (0)	0% (0)	0% (0)
Azathioprine/mercaptopurine	68% (13)	29% (18)	37% (48)
5-aminosalicylic acid	5% (1)	16% (10)	12% (16)
Antibiotics	5% (1)	13% (8)	10% (13)
Anti-TNF $\alpha$	0% (0)	0% (0)	0% (0)
Ciclosporin	0% (0)	0% (0)	0% (0)
Dietary therapy	42% (8)	21% (13)	36% (47)
Golimumab	0% (0)	0% (0)	0% (0)
Humira	0% (0)	2% (1)	0% (0)
Inflectra	0% (0)	0% (0)	0% (0)
Methotrexate	5% (1)	6% (4)	7% (9)
Mycophenolate	0% (0)	0% (0)	0% (0)
Remicade	0% (0)	0% (0)	0% (0)
Remsima	0% (0)	0% (0)	0% (0)
Steroids	26% (5)	40% (25)	50% (64)
Tacrolimus	0% (0)	2% (1)	0% (0)
Topical	0% (0)	3% (2)	2% (2)
Ustekinumab	0% (0)	0% (0)	0% (0)
Vedolizumab	0% (0)	0% (0)	0% (0)
Other	0% (0)	2% (1)	0% (0)

CD = Crohn's disease; TNF $\alpha$  = tumour necrosis factor alpha.

CD: initial treatment	Frequency (% , n)		
	Adalimumab (Humira) (n=19)	Infliximab (Inflectra/Remsima) (n=63)	Infliximab (Remicade) (n=129)
<b>Treatment details</b>			
<b>Pre-treatment screening in relation to initiation on anti-TNF<math>\alpha</math></b>			
<b>Chest X-ray</b>	<b>(n=17)</b>	<b>(n=43)</b>	<b>(n=103)</b>
Yes	100% (17)	81% (35)	90% (93)
No	0% (0)	12% (5)	10% (10)
Not indicated	0% (0)	7% (3)	0% (0)
<b>Mantoux screen</b>	<b>(n=17)</b>	<b>(n=43)</b>	<b>(n=103)</b>
Yes	12% (2)	5% (2)	7% (7)
No	88% (15)	61% (26)	78% (80)
Not indicated	0% (0)	35% (15)	16% (16)
<b>TB screen</b>	<b>(n=17)</b>	<b>(n=43)</b>	<b>(n=103)</b>
Yes	71% (12)	74% (32)	84% (86)
No	18% (3)	23% (10)	12% (12)
Not indicated	12% (2)	2% (1)	5% (5)
<b>Stool cultures</b>	<b>(n=17)</b>	<b>(n=43)</b>	<b>(n=103)</b>
Yes	53% (9)	63% (27)	40% (41)
No	29% (5)	12% (5)	52% (53)
Not indicated	18% (3)	26% (11)	9% (9)
<b>Hepatitis B</b>	<b>(n=17)</b>	<b>(n=43)</b>	<b>(n=103)</b>
Yes	82% (14)	70% (30)	49% (50)
No	12% (2)	28% (12)	45% (46)
Not indicated	6% (1)	2% (1)	7% (7)

CD = Crohn's disease; TNF $\alpha$  = tumour necrosis factor alpha.

National clinical audit of biological therapies. Full national audit results – paediatric services. September 2016. UK IBD audit

CD: initial treatment	Frequency (% , n)		
	Adalimumab (Humira) (n=19)	Infliximab (Inflectra/Remsima) (n=63)	Infliximab (Remicade) (n=129)
<b>Treatment details</b>			
<b>Pre-treatment screening in relation to initiation on anti-TNF<math>\alpha</math> (continued)</b>			
<b>Hepatitis C</b>	<b>(n=17)</b>	<b>(n=43)</b>	<b>(n=103)</b>
Yes	82% (14)	56% (24)	33% (34)
No	12% (2)	42% (18)	59% (61)
Not indicated	6% (1)	2% (1)	8% (8)
<b>HIV screen</b>	<b>(n=17)</b>	<b>(n=43)</b>	<b>(n=103)</b>
Yes	0% (0)	23% (10)	5% (5)
No	29% (5)	58% (25)	75% (77)
Not indicated	71% (12)	19% (8)	20% (21)
<b>Varicella screen</b>	<b>(n=17)</b>	<b>(n=43)</b>	<b>(n=103)</b>
Yes	100% (17)	86% (37)	83% (85)
No	0% (0)	9% (4)	13% (13)
Not indicated	0% (0)	5% (2)	5% (5)
<b>C. difficile test</b>	<b>(n=17)</b>	<b>(n=43)</b>	<b>(n=103)</b>
Yes	53% (6)	54% (23)	27% (28)
No	41% (7)	26% (11)	61% (63)
Not indicated	24% (4)	21% (9)	12% (12)
<b>Severity of disease</b>	<b>(n=17)</b>	<b>(n=43)</b>	<b>(n=103)</b>
Remission	0% (0)	0% (0)	0% (0)
Mild	0% (0)	14% (6)	7% (7)
Moderate	82% (14)	40% (17)	61% (63)
Severe	18% (3)	47% (20)	32% (33)

CD = Crohn's disease; TNF $\alpha$  = tumour necrosis factor alpha.

## Crohn's disease follow-up treatment at 3 months

CD: follow-up treatment at 3 months	Frequency (% , n)		
	Adalimumab (Humira) (n=5)	Infliximab (Inflectra/Remsima) (n=34)	Infliximab (Remicade) (n=54)
<b>Follow-up treatment details</b>			
<b>Review of treatment plan</b>			
Continue treatment	-	100% (34)	94% (50)
Stop treatment	-	0% (0)	4% (2)
Escalate treatment	-	0% (0)	2% (1)
<b>If treatment was stopped or escalated, what were the reasons?</b>			<b>(n=3)</b>
Poor response	-	0% (0)	33% (1)
Side effects / adverse events	-	0% (0)	33% (1)
Other	-	0% (0)	33% (1)
<b>Were there any adverse reactions since the last review?</b>			
Yes	-	6% (2)	7% (4)
<b>What adverse reactions (more than one may have been selected)?</b>			
Infection	-	0% (0)	2% (1)
Breathing difficulty	-	0% (0)	2% (1)
Blood abnormality	-	0% (0)	2% (1)
Rash	-	6% (2)	0% (0)
Other	-	0% (0)	2% (1)

CD = Crohn's disease.

National clinical audit of biological therapies. Full national audit results – paediatric services. September 2016. UK IBD audit

CD: follow-up treatment at 3 months	Frequency (% , n)		
	Adalimumab (Humira) (n=5)	Infliximab (Inflectra/Remsima) (n=34)	Infliximab (Remicade) (n=54)
<b>Follow-up treatment details</b>			
<b>Is the patient currently receiving any other therapies for the management of their IBD?</b>			
Yes	-	94% (32)	85% (46)
<b>If yes, which other therapies?</b>			
Azathioprine/mercaptopurine	-	82% (28)	78% (42)
Antibiotics	-	6% (2)	11% (6)
Topical	-	0% (0)	0% (0)
Methotrexate	-	6% (2)	2% (1)
Dietary therapy	-	6% (2)	9% (5)
5-aminosalicylic acid	-	12% (4)	22% (12)
Steroids	-	6% (2)	11% (6)
Mycophenolate	-	0% (0)	0% (0)
Ciclosporin	-	0% (0)	0% (0)
Other	-	9% (3)	0% (0)
<b>Severity of disease</b>		<b>(n=25)</b>	<b>(n=36)</b>
Remission	-	28% (7)	42% (15)
Mild	-	40% (10)	31% (11)
Moderate	-	28% (7)	19% (7)
Severe	-	4% (1)	8% (3)

IBD = inflammatory bowel disease; CD = Crohn's disease.



## Ulcerative colitis disease details

UC: disease details	Frequency (% , n)		
	Adalimumab (Humira) (n=1)	Infliximab (Inflectra/RemSIMA) (n=14)	Infliximab (Remicade) (n=32)
<b>Diagnosis</b>			
<b>Maximal disease distribution at the time of decision to initiate biological therapy, as defined by the Montreal classification</b>			
Proctitis (E1)	-	14% (2)	9% (3)
Left sided (E2)	-	14% (2)	16% (5)
Extensive (E3)	-	71% (10)	75% (24)

UC = ulcerative colitis.

## Ulcerative colitis initial treatment

UC: initial treatment	Frequency (% , n)		
	Adalimumab (Humira) (n=1)	Infliximab (Inflectra/RemSIMA) (n=14)	Infliximab (Remicade) (n=32)
<b>Treatment details</b>			
<b>Is the patient biologics naïve?</b>			
Yes	-	100% (14)	100% (32)
<b>Time between date of diagnosis and date of initial treatment</b>			
<1 year	-	50% (7)	44% (14)
1–2 years	-	50% (7)	41% (13)
3–5 years	-	0% (0)	13% (4)
6–10 years	-	0% (0)	3% (1)
<b>What was the clinical indication for this treatment?</b>			
Acute severe UC	-	43% (6)	56% (18)
Chronic refractory UC	-	57% (8)	44% (14)

UC = ulcerative colitis.

National clinical audit of biological therapies. Full national audit results – paediatric services. September 2016. UK IBD audit

UC: initial treatment	Frequency (% , n)		
	Adalimumab (Humira) (n=1)	Infliximab (Inflectra/Remsima) (n=14)	Infliximab (Remicade) (n=32)
<b>Treatment details</b>			
<b>Were any acute reactions or adverse events recorded for this treatment?</b>			
Yes	-	0% (0)	0% (0)
<b>Is the patient receiving any concomitant therapies for the management of IBD at the time of this treatment?</b>			
Yes	-	93% (13)	97% (31)
<b>If yes, indicate which concomitant therapies (more than one may have been selected)</b>			
Allopurinol	-	0% (0)	0% (0)
Azathioprine/mercaptopurine	-	50% (7)	72% (23)
5-aminosalicylic acid	-	64% (9)	50% (16)
Antibiotics	-	0% (0)	3% (1)
Ciclosporin	-	0% (0)	6% (2)
Dietary therapy	-	0% (0)	0% (0)
Methotrexate	-	7% (1)	0% (0)
Mycophenolate	-	0% (0)	0% (0)
Steroids	-	71% (10)	72% (23)
Tacrolimus	-	0% (0)	0% (0)
Topical	-	7% (1)	16% (5)
Other	-	14% (2)	9% (3)

IBD = inflammatory bowel disease; UC = ulcerative colitis.

UC: initial treatment	Frequency (% , n)		
	Adalimumab (Humira) (n=1)	Infliximab (Inflectra/Remsima) (n=14)	Infliximab (Remicade) (n=32)
<b>Treatment details</b>			
<b>Has the patient failed to respond or are they intolerant to immunosuppressive drugs / corticosteroids?</b>			
Yes	-	93% (13)	97% (31)
<b>If yes, indicate which previous therapies (more than one may have been selected)</b>			
Azathioprine/mercaptopurine	-	64% (9)	69% (22)
5-aminosalicylic acid	-	21% (3)	47% (15)
Antibiotics	-	0% (0)	6% (2)
Ciclosporin	-	0% (0)	6% (2)
Dietary therapy	-	0% (0)	6% (2)
Humira	-	0% (0)	3% (1)
Methotrexate	-	14% (2)	0% (0)
Steroids	-	86% (12)	84% (27)
Topical	-	0% (0)	6% (2)
<b>Pre-treatment screening in relation to initiation on anti-TNF<math>\alpha</math></b>			
<b>Chest X-ray</b>			
Yes	-	100% (14)	100% (32)
No	-	0% (0)	0% (0)
Not indicated	-	0% (0)	0% (0)
<b>Mantoux screen</b>			
Yes	-	7% (1)	3% (1)
No	-	57% (8)	84% (27)
Not indicated	-	36% (5)	13% (4)

UC = ulcerative colitis.

National clinical audit of biological therapies. Full national audit results – paediatric services. September 2016. UK IBD audit

UC: initial treatment	Frequency (% , n)		
	Adalimumab (Humira) (n=1)	Infliximab (Inflectra/Remsima) (n=14)	Infliximab (Remicade) (n=32)
<b>Treatment details</b>			
<b>Pre-treatment screening in relation to initiation on anti-TNF<math>\alpha</math> (continued)</b>			
<b>TB screen</b>			
Yes	-	57% (8)	84% (27)
No	-	29% (4)	16% (5)
Not indicated	-	14% (2)	0% (0)
<b>Stool cultures</b>			
Yes	-	86% (12)	72% (23)
No	-	14% (2)	22% (7)
Not indicated	-	0% (0)	6% (2)
<b>Hepatitis B</b>			
Yes	-	71% (10)	78% (25)
No	-	29% (4)	16% (5)
Not indicated	-	0% (0)	6% (2)
<b>Hepatitis C</b>			
Yes	-	64% (9)	63% (20)
No	-	36% (5)	28% (9)
Not indicated	-	0% (0)	9% (3)
<b>HIV screen</b>			
Yes	-	29% (4)	13% (4)
No	-	43% (6)	72% (23)
Not indicated	-	29% (4)	16% (5)

TNF $\alpha$  = tumour necrosis factor alpha; UC = ulcerative colitis.

UC: initial treatment	Frequency (% , n)		
	Adalimumab (Humira) (n=1)	Infliximab (Inflectra/Remsima) (n=14)	Infliximab (Remicade) (n=32)
<b>Treatment details</b>			
<b>Pre-treatment screening in relation to initiation on anti-TNF<math>\alpha</math> (continued)</b>			
<b>Varicella screen</b>			
Yes	-	93% (13)	81% (26)
No	-	7% (1)	9% (3)
Not indicated	-	0% (0)	9% (3)
<b>C. difficile test</b>			
Yes	-	86% (12)	53% (17)
No	-	14% (2)	31% (10)
Not indicated	-	0% (0)	16% (5)
<b>Severity of disease</b>			
Remission	-	0% (0)	0% (0)
Mild	-	0% (0)	9% (3)
Moderate	-	64% (9)	38% (12)
Severe	-	36% (5)	53% (17)

TNF $\alpha$  = tumour necrosis factor alpha; UC = ulcerative colitis.

## Ulcerative colitis follow-up treatment at 3 months

UC: follow-up treatment at 3 months	Frequency (% , n)		
	Adalimumab (Humira) (n=0)	Infliximab (Inflectra/Remsima) (n=4)	Infliximab (Remicade) (n=14)
<b>Follow-up treatment details</b>			
<b>Review of treatment plan</b>			
Continue treatment	-	-	93% (13)
Escalate treatment	-	-	7% (1)
<b>If treatment was stopped or escalated, what were the reasons?</b>			
Poor response	-	-	100% (1)
<b>Were there any adverse reactions since the last review?</b>			
Yes	-	-	0% (0)
<b>Is the patient currently receiving any other therapies for the management of their IBD?</b>			
Yes	-	-	100% (14)
<b>If yes, which other therapies?</b>			
Azathioprine/mercaptopurine	-	-	86% (12)
Antibiotics	-	-	7% (1)
5-aminosalicylic acid	-	-	36% (5)
Steroids	-	-	36% (5)
Other	-	-	7% (1)
<b>Severity of disease</b>			
Remission	-	-	21% (3)
Mild	-	-	43% (6)
Moderate	-	-	29% (4)
Severe	-	-	7% (1)

IBD = inflammatory bowel disease; UC = ulcerative colitis.

## Inflammatory bowel disease unclassified disease details

IBDU: disease details	Frequency (% , n)		
	Adalimumab (Humira) (n=1)	Infliximab (Inflectra/Remsima) (n=5)	Infliximab (Remicade) (n=14)
<b>Diagnosis</b>			
<b>Maximal disease distribution at the time of decision to initiate biological therapy, as defined by the Montreal classification</b>			
Left sided (E2)	-	-	29% (4)
Extensive (E3)	-	-	71% (10)

IBDU = inflammatory bowel disease unclassified.

## Inflammatory bowel disease unclassified initial treatment

IBDU: initial treatment	Frequency (% , n)		
	Adalimumab (Humira) (n=1)	Infliximab (Inflectra/Remsima) (n=5)	Infliximab (Remicade) (n=14)
<b>Treatment details</b>			
<b>Is the patient biologics naïve?</b>			
Yes	-	-	100% (14)
<b>Time between date of diagnosis and date of initial treatment</b>			
<1 year	-	-	43% (6)
1–2 years	-	-	29% (4)
3–5 years	-	-	21% (3)
6–10 years	-	-	7% (1)
<b>What was the clinical indication for this treatment?</b>			
Acute severe IBDU	-	-	43% (6)
Chronic refractory IBDU	-	-	50% (7)
Other clinical indication	-	-	7% (1)
<b>Were any acute reactions or adverse events recorded for this treatment?</b>			
Yes	-	-	0% (0)

IBDU = inflammatory bowel disease unclassified.

National clinical audit of biological therapies. Full national audit results – paediatric services. September 2016. UK IBD audit

IBDU: initial treatment	Frequency (% , n)		
	Adalimumab (Humira) (n=1)	Infliximab (Inflectra/Remsima) (n=5)	Infliximab (Remicade) (n=14)
<b>Treatment details</b>			
<b>Is the patient receiving any concomitant therapies for the management of IBD at the time of this treatment?</b>			
Yes	-	-	100% (14)
<b>If yes, indicate which concomitant therapies (more than one may have been selected)</b>			
Azathioprine/mercaptopurine	-	-	57% (8)
5-aminosalicylic acid	-	-	43% (6)
Antibiotics	-	-	7% (1)
Dietary therapy	-	-	7% (1)
Methotrexate	-	-	14% (2)
Steroids	-	-	36% (5)
Other	-	-	7% (1)
<b>Has the patient failed to respond or are they intolerant to immunosuppressive drugs / corticosteroids?</b>			
Yes	-	-	71% (10)
<b>If yes, indicate which previous therapies (more than one may have been selected)</b>			
Azathioprine/mercaptopurine	-	-	50% (7)
5-aminosalicylic acid	-	-	21% (3)
Dietary therapy	-	-	29% (4)
Methotrexate	-	-	7% (1)
Steroids	-	-	57% (8)
<b>Pre-treatment screening in relation to initiation on anti-TNFα</b>			
<b>Chest X-ray</b>			
Yes	-	-	93% (13)
No	-	-	7% (1)
Not indicated	-	-	0% (0)

IBD = inflammatory bowel disease; IBDU = inflammatory bowel disease unclassified.



IBDU: initial treatment	Frequency (% , n)		
	Adalimumab (Humira) (n=1)	Infliximab (Inflectra/Remsima) (n=5)	Infliximab (Remicade) (n=14)
<b>Treatment details</b>			
<b>Pre-treatment screening in relation to initiation on anti-TNF<math>\alpha</math> (continued)</b>			
<b>Mantoux screen</b>			
Yes	-	-	7% (1)
No	-	-	79% (11)
Not indicated	-	-	14% (2)
<b>TB screen</b>			
Yes	-	-	71% (10)
No	-	-	29% (4)
Not indicated	-	-	0% (0)
<b>Stool cultures</b>			
Yes	-	-	57% (8)
No	-	-	21% (3)
Not indicated	-	-	21% (3)
<b>Hepatitis B</b>			
Yes	-	-	57% (8)
No	-	-	43% (6)
Not indicated	-	-	0% (0)
<b>Hepatitis C</b>			
Yes	-	-	29% (4)
No	-	-	64% (9)
Not indicated	-	-	7% (1)

IBDU = inflammatory bowel disease unclassified; TNF $\alpha$  = tumour necrosis factor alpha.

National clinical audit of biological therapies. Full national audit results – paediatric services. September 2016. UK IBD audit

IBDU: initial treatment	Frequency (% , n)		
	Adalimumab (Humira) (n=1)	Infliximab (Inflectra/Remsima) (n=5)	Infliximab (Remicade) (n=14)
<b>Treatment details</b>			
<b>Pre-treatment screening in relation to initiation on anti-TNF<math>\alpha</math> (continued)</b>			
<b>HIV Screen</b>			
Yes	-	-	7% (1)
No	-	-	86% (12)
Not indicated	-	-	7% (1)
<b>Varicella screen</b>			
Yes	-	-	86% (12)
No	-	-	7% (1)
Not indicated	-	-	7% (1)
<b>C. difficile test</b>			
Yes	-	-	50% (7)
No	-	-	43% (6)
Not indicated	-	-	7% (1)
<b>Severity of disease</b>			
Remission	-	-	0% (0)
Mild	-	-	7% (1)
Moderate	-	-	50% (7)
Severe	-	-	43% (6)

IBDU = inflammatory bowel disease unclassified; TNF $\alpha$  = tumour necrosis factor alpha.

## Inflammatory bowel disease unclassified follow-up treatment at 3 months

IBDU: follow-up treatment at 3 months	Frequency (% , n)		
	Adalimumab (Humira) (n=1)	Infliximab (Inflectra/Remsima) (n=1)	Infliximab (Remicade) (n=7)
<b>Follow-up treatment details</b>			
<b>Review of treatment plan</b>			
Continue treatment	-	-	100% (7)
<b>Were there any adverse reactions since the last review?</b>			
Yes	-	-	0% (0)
<b>Is the patient currently receiving any other therapies for the management of their IBD?</b>			
Yes	-	-	100% (7)
<b>If yes, which other therapies?</b>			
Azathioprine/mercaptopurine	-	-	43% (3)
Antibiotics	-	-	14% (1)
Methotrexate	-	-	29% (2)
5-aminosalicylic acid	-	-	57% (4)
Steroids	-	-	71% (5)
<b>Severity of disease</b>			
Remission	-	-	14% (1)
Mild	-	-	29% (2)
Moderate	-	-	57% (4)
Severe	-	-	0% (0)

IBD = inflammatory bowel disease; IBDU = inflammatory bowel disease unclassified.